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Background: The rising financial burden of cancer on health-care systems worldwide has led to the increased demand for
evidence-based research on which to base reimbursement decisions. Economic evaluations are an integral component of this
necessary research. Ascertainment of reliable health-care cost and quality-of-life estimates to inform such studies has historically
been challenging, but recent advances in informatics in the United Kingdom provide new opportunities.
Methods: The costs of hospital care for breast, colorectal and prostate cancer disease-free survivors were calculated over 15
months from initial diagnosis of cancer using routinely collected data within a UK National Health Service (NHS) Hospital Trust.
Costs were linked at patient level to patient-reported outcomes and registry-derived sociodemographic factors. Predictors of cost
and the relationship between costs and patient-reported utility were examined.
Results: The study population included 223 breast cancer patients, 145 colorectal and 104 prostate cancer patients. The mean
15-month cumulative health-care costs were d12595 (95% CI d11517–d13722), d12643 (d11282–d14102) and d3722 (d3263–d4208),
per-patient respectively. The majority of costs occurred within the first 6 months from diagnosis. Clinical stage was the most important
predictor of costs for all cancer types. EQ-5D score was predictive of costs in colorectal cancer but not in breast or prostate cancer.
Conclusion: It is now possible to evaluate health-care cost using routine NHS data sets. Such methods can be utilised in future
retrospective and prospective studies to efficiently collect economic data.
The cost of cancer is much discussed and of considerable relevance
internationally given rising health-care costs and financial
constraint. The initial treatment period, rehabilitation and early
follow-up after a new diagnosis of cancer incurs heavy resource
demands on secondary care. Characterisation and prediction of
these costs alongside other health outcomes is important for
health-care budget planning and service design, aiming at
improved efficiency. In particular, economic evaluation is increas-
ingly used to inform the allocation of scarce health resources, and
many national reimbursement bodies (including the National
Institute for Health and Care Excellence (NICE) in the United
Kingdom) require the use of patient quality-adjusted life-years
(QALYs) as an endpoint in economic evaluations (Drummond
et al, 2005). Reliable analyses therefore require robust estimation of
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costs and patient quality-of-life (QoL). There have been several
attempts to describe the cost of cancer using insurance claims,
registry data or manual case-note audit (Brown et al, 1999; Karnon
et al, 2007; Yabroff et al, 2008; Krahn et al, 2010; Mariotto et al,
2011; Tilson et al, 2012; De Oliveira et al, 2013). Methods applied
in the United Kingdom, where detailed claims databases do not
exist, either fail to capture local variation and full data granularity
or require a heavy data collection burden; accurate and easily
reproducible estimates of the true cost of care therefore remain
elusive. In the United Kingdom, the National Health Service (NHS)
provides universal publically funded health-care, which operates
financially through a system of commissioning for services.
Payments for defined episodes of care are calculated using a
national tariff. In an attempt to improve the accuracy and national
standardisation of the methods used to calculate this national tariff,
Patient Level Information and Costing Systems (PLICS) are being
developed (Francisci et al, 2013). Local pilots promoting national
standardisation of methods using PLICS are on-going, under
guidance from the Department of Health. It is hoped that such
systems, if fully implemented, will promote the ability to generate
efficiency savings through improved service evaluation and
planning (Blunt and Bardsley, 2012; Vogl, 2012). Patient-level-
costing systems provide new opportunities for the calculation of
the complete hospital-based cost of care. By accurately capturing
patient-level variation they offer an improvement over current
methods, which rely on coded Human Resource Groups (HRGs)
and assigned national standard tariffs.
It is now accepted that the assessment of patient’s QoL should
be embedded in routine care (Black, 2013). The NHS Patient
Reported Outcome Measures (PROMS) initiative routinely collects
QoL data from a number of patient groups in England and is soon
to be rolled out to cancer patients (Glaser et al, 2013). Identifying
an efficient method to collect routine PROMs data linked to
clinical and financial data sets is an essential prerequisite for robust
future economic evaluation of cancer services. The electronic
Patient-reported Outcomes from Cancer Survivors (ePOCS)
project has designed and tested the technical and clinical feasibility
of an electronic system for collecting patient-reported outcome
data online and linking this with clinical cancer registry data
(Ashley et al, 2011b); through data linkage mechanisms, it is now
possible to also connect cost data with PROMS data using this new
system.
The primary aim of this paper is to describe the direct costs of
hospital-based care for patients following a diagnosis of breast,
colorectal or prostate cancer using routine NHS data. In particular,
it aims to confirm the feasibility of data linkage between a new
patient-level hospital finance system, electronic clinical records and
electronically captured PROMs. The resulting composite data set is
then used to explore the extent to which clinical and socio-
demographic factors predict NHS costs and QoL over a 15-month
period.
PATIENTS AND METHODS
The costs of hospital-based care for breast, colorectal and prostate
cancer disease-free survivors were calculated over 15 months from
initial diagnosis of cancer using data collected during a feasibility
study of the ePOCS system. The ePOCS system is a novel
electronic system for collecting patient-reported outcomes online
and linking them with clinical cancer registry data. The feasibility
study included collection of patient clinical, sociodemographic,
cost and QoL data, which were used in this analysis to explore total
15-month cumulative costs, cost predictors and patient utility for
disease-free survivors. Comprehensive accounts of the design and
development of the ePOCS system, and the protocol and results of
the feasibility study have been published open-access (Ashley et al,
2011a, 2013). In brief, English-literate adult patients within 6
months of a diagnosis of early breast, colorectal or prostate cancer
being treated with curative intent were recruited from Leeds
Teaching Hospitals NHS Trust (LTHT) and Calderdale &
Huddersfield NHS Foundation Trust (CHFT). Eligible patients
were identified during routine multidisciplinary meetings and/or
through consultation of medical notes by NHS research nurses
and/or oncology clinicians. The recruitment period was November
2010 to September 2011. Participants were asked to complete
PROMs online using the ePOCS system at three time points: T1,
within 6 months of diagnosis, T2 at 9 months post diagnosis and
T3 at 15 months post-diagnosis. The PROMs data were linked with
patients’ clinical registry data and stored in the National Cancer
Data Repository.
The cost analysis included all hospital-based costs incurred over
the 15-month follow-up period in the LTHT population. Day zero
was defined as the date of diagnosis, recorded from the medical
notes by the research nurse at the time of patient consent to the
ePOCS study. Patients were diagnosed between May 2010 and
September 2011. Costs were adjusted to the common base year of
2011–2012 using the Personal Social Services Research Unit
(PSSRU) Hospital and community health services pay and prices
index. Confidence intervals were calculated for all analyses using
the bootstrap method. Analysis of costs was conducted using
regression analysis performed on log-costs, which were approxi-
mately normally distributed and did not contain zeros, using the
ordinary least squares method. The explanatory variables age,
gender, oncological stage, Index of Multiple Deprivation (IMD)
and baseline EQ-5D (T1) were established a priori; all of which
were included in univariate and multivariate analyses. Complete
case analysis was used for individual EQ-5D regressions. The
complete 15 months of follow-up was available for all patients.
Patients who died or suffered a cancer relapse (i.e., ceased to be
disease free) during this period were identified from the clinical
record and excluded on the grounds that this study reports the
outcomes specific to disease-free survivors. All analysis was
carried out using the R statistical software package version 3.0.0
(R Development Core Team 2009).
Data capture and linkage. The cost analysis was based on finance
data from patients recruited at LTHT only, owing to the fact that
PLICS data were unavailable for patients recruited at CHFT.
PROMs data were available from both LTHT and CHFT; the
analysis of patient utility therefore utilised data from patients
recruited at both LTHT and CHFT.
Clinical data. The LTHT Oncology department uses a computer-
based system called Patient Pathway Manager (PPM), which links
the various clinical data systems within the LTHT and maintains
an electronic patient record. PPM includes information on
demographics, pathology, radiology, surgery, chemotherapy and
radiotherapy. The ePOCS study information was also held within
PPM, allowing internal linkage of ePOCS study ID, NHS number
and other identifiers (Newsham et al, 2011).
Finance data. Patient records within LTHT from PPM were
individually linked to costs held within the local pilot database of
the national PLICS scheme using each patient’s NHS number. This
provides a cost for hospital-based accident and emergency
department visits, outpatient attendances and inpatient stays.
Individual care episodes are coded using the national HRG version 4
codes. HRG costing uses a mixture of (a) top–down costing –
where cost pools (used to collect indirect and overhead costs) are
allocated to HRGs using the total cost of that cost pool weighted
for each HRG based upon the best available data and, (b) bottom–
up costing – which builds up the costs of an HRG from known
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local expenditure (e.g., prosthetics in hip replacement) HRGs
(Department of Health Payment by Results team, 2012). HRG
codes include the average cost of intravenous and oral
chemotherapies.
Socioeconomic data. A marker of socioeconomic status was
ascertained by calculating IMD scores and quintiles from patients’
postcodes recorded in PPM; the first quintile contains patients
living in the most deprived areas and the fifth quintile contains
patients living in the least deprived areas (Department for
Communities and Local Government, 2010).
Patient-reported outcome data. Over the three time points,
participants treated at LTHT and CHFT were asked to complete
a range of PROMs, which assessed patients’ psychosocial and
sociodemographic status (e.g., education level, employment status
etc.), QoL and disease specific (breast, colorectal and prostate
cancer) variables. The analysis presented here utilises PROMs data
on patient health status as measured by the EQ-5D version 2
questionnaire, collected at T1, T2 and T3. Complete case analysis
was used to maximise reproducibility in future studies that build
on this pilot.
The EQ-5D questionnaire measures health status across five
domains: mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Respondents specify whether they have no
problems, some problems or severe problems within each domain,
on the day of response. Utility scores were derived from the EQ-5D
responses using preferences for health states elicited from the UK
general public (The EuroQol Group, 1990; Gudex et al, 1995). A
maximum utility score of 1 represents the state of being in full
health; zero represents the state of being dead. The EQ-5D has
been used widely in cancer studies (Pickard et al, 2007b), and is
regarded as the gold-standard measure of QoL in the United
Kingdom as specified by NICE for the calculation of QALYs. We
compared patients’ utility scores with age- and sex-matched
population norms obtained from a survey of the UK population
(Kind et al, 1998).
Ethical approval was given for the ePOCS study from the NHS
Leeds (East) Research Ethics Committee (10/H1306/65). Patients
provided the written informed consent.
RESULTS
Patient characteristics. In total, there were 636 patients consented
into the ePOCS study across LTHT and CHFT. The mean patient
age was 63 (range 23–92). Full details of the patient demographics
and baseline characteristics are available in the open-access ePOCS
study feasibility report (Ashley et al, 2013). There were 297 patients
with breast cancer, 192 with colorectal cancer and 147 with
prostate cancer. Patients not classified as survivors within the
15-month-study period were excluded; these included patients who
developed new primary cancers, recurrent cancer or had died. The
final study population meeting eligibility consisted of 223 patients
with breast cancer, 145 with colorectal cancer and 104 with
prostate cancer from LTHT, and 68 with breast cancer, 19 with
colorectal cancer and 36 with prostate cancer from CHFT (see
Figure 1). Baseline patient characteristics are described in Table 1.
Overall, the mean age was 56 (median 55, s.d. 10.7) for the breast
patients, 63 (median 63, s.d. 9.1) for the colorectal patients and 65
(median 65, s.d. 6.6) for the prostate patients. For the cost analysis,
complete data were available. For the analysis of patient utility,
over 92% of EQ-5D questionnaires were returned at 6 months
across all cancers, however this dropped to around 70% at 15
months for breast and colorectal cancer, and 82% for prostate
cancer, respectively. Using the NHS number alone, linkage between
the LTHT PLICS finance database, the electronic clinical record
and the ePOCS study database was 100%.
Hospital costs. Costs for breast and colorectal cancer were similar
and considerably higher than those for prostate cancer. For breast
cancer patients, the mean cumulative hospital costs at 6, 9 and 15
months (with 95% CIs) were d9557 (d8893–d10 220), d11 175
(d10 339–d12 059) and d12 595 (d11 517–d13 722), respectively.
For colorectal cancer, the corresponding figures were d10 038
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Figure 1. Flowchart describing eligible patients.
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(d9015–d11 131), d11 809 (d10 551–d13 109) and d12 643
(d11 282–d14 102) and for prostate cancer d2807 (d2398–d3233),
d3407 (d2977–d3846) and d3722 (d3263–d4208). In each cancer,
at least 75% of the total costs at month 15 were incurred by month 6.
Figure 2 illustrates the decline in costs over time in all cancers with
small rises around the 6- and 12-month follow-up visits.
The mean costs by subgroup suggest that the below 65 age
group incurred greater costs than the 65 and over group and that
Table 1. Patient characteristics—numbers of patients (%)
Breast Colorectal Prostate
Characteristic (%) QOL data Cost data QOL data Cost data QOL data Cost data
Patients consented 297 192 147
Eligible patients 291 164 140
Patients analysed 250 223 135 146 130 104
EQ-5D questionnaire returns
6 months 231 (92.4) 128 (94.8) 126 (96.9)
12 months 186 (74.4) 101 (74.8) 109 (83.8)
15 months 177 (70.8) 97 (71.9) 106 (81.5)
Sex
Male 1 (0.4) 2 (0.9) 86 (63.7) 89 (61.0)
Female 249 (99.6) 221 (99.1) 49 (36.3) 57 (39.0)
Age
o65 194 (77.6) 172 (77.1) 76 (56.3) 80 (54.8) 58 (44.6) 50 (48.1)
X65 56 (22.4) 51 (22.9) 59 (43.7) 66 (45.2) 72 (55.4) 54 (51.9)
IMD
1 48 (19.2) 47 (21.1) 25 (18.) 32 (21.9) 14 (10.8) 12 (11.5)
2 45 (18.0) 42 (18.8) 30 (22.2) 31 (21.2) 21 (16.2) 16 (15.4)
3 33 (13.2) 28 (12.6) 24 (17.8) 25 (17.1) 24 (18.5) 20 (19.2)
4 71 (28.4) 58 (26.0) 30 (22.2) 34 (23.3) 36 (27.7) 28 (26.9)
5 53 (21.2) 48 (21.5) 26 (19.3) 24 (16.4) 35 (26.9) 28 (26.9)
HER2 status
Positive 13 (5.2) 17 (7.6)
Negative 138 (55.2) 158 (70.9)
Unknown 99 (39.6) 48 (21.5)
Hormone receptor
Positive 158 (63.2) 139 (62.3)
Negative 92 (36.8) 84 (37.7)
Lymph nodes
N0 125 (50.0) 140 (62.8)
N positive 47 (18.8) 57 (25.6)
Unknown 78 (31.2) 26 (11.7)
Primary tumour
T1 112 (44.8) 133 (59.6)
T2 51 (20.4) 55 (24.7)
T3 6 (2.4) 7 (3.1)
T4 0 (0) 0 (0)
Unknown 81 (32.4) 28 (12.6)
Grade
1 43 (17.2) 51 (22.9)
2 106 (42.4) 95 (42.6)
3 56 (22.4) 53 (23.8)
Unknown 45 (18.0) 24 (10.8)
Dukes staging
A 15 (11.1) 19 (13.0)
B 25 (18.5) 31 (21.2)
C 19 (14.1) 26 (17.8)
D 1 (0.7) 1 (0.7)
Unknown 75 (55.6) 69 (47.3)
Gleason score
0–5 0 (0) 0 (0)
6 36 (27.7) 28 (26.9)
7 60 (46.2) 56 (53.8)
8 2 (1.5) 2 (1.9)
9 9 (6.9) 7 (6.7)
10 0 (0) 0 (0)
Unknown 23 (17.7) 11 (10.6)
Abbreviations: HER2¼ human epidermal growth factor receptor 2; IMD¼ Index of Multiple Deprivation; QoL¼quality of life.
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costs increase with disease stage (Figure 3). Tables 2 and 3 include
the univariate and multivariate analyses, respectively, predicting
15-month costs. In each case, disease stage appears to be the
strongest predictor of costs.
Utility. Figure 4 depicts the mean EQ-5D score at 6, 9 and 15
months for each of the three cancer types. The mean EQ-5D scores
for patients with each cancer type increased over time, generally
plateauing after 1 year from diagnosis. Breast cancer patients had
the worst utility and the smallest improvements over time, which
may reflect more aggressive adjuvant treatment over a longer time
period compared with the two other cancer types. Older breast
cancer patients also had higher utility than younger patients across
the three time points, possibly for the same reasons. There was a
trend suggesting that those living in areas of higher deprivation
(lower IMD groups) had lower QoL scores compared with those
living in more affluent areas. However, the multivariate regression
of the EQ-5D scores (results in Supplementary Material) found no
significant predictors of utility at any time point for any cancer.
A full breakdown of the cumulative costs and EQ-5D score at 6,
9 and 15 months from diagnosis for each tumour type, clinical
subgroups and treatment modalities is provided in the
Supplementary Appendix. EQ-5D score at T3 demonstrated only
minimal correlation with cumulative costs with a Pearson’s
correlation coefficient of  0.06 for breast cancer,  0.20 for
colorectal cancer and  0.10 for prostate cancer. A low EQ-5D
score at T1 was associated with higher 15 month cumulative costs
but this only reached statistical significance in univariate and
multivariate analysis for colorectal cancer (Tables 2 and 3).
Comparisons with population norms indicated that breast
cancer patients had significantly lower EQ-5D score than an age-
and sex-matched reference population. Conversely, prostate cancer
patients were found to have significantly higher scores than the
reference population. No significant difference was found for
colorectal cancer patients (Table 4).
DISCUSSION
Traditionally cost and cost-effectiveness analyses in the United
Kingdom have used techniques such as hand-searching patient
records, asking patients to complete resource use questionnaires or
use of a combination of different methods from diverse sources in
order to collect cost and outcomes data (Karnon et al, 2007). For
studies with large sample sizes and longitudinal analyses, these
methods are particularly time consuming and have the potential
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for bias due to discrepancies in records both within and between
facilities. More recently, use of Hospital Episode Statistics (HES)
has gained popularity within cost analysis (Gaughan et al, 2012).
HES provides electronic access to over 125 million outpatient,
inpatient and accident and emergency attendances in England and
is increasingly used for economic analysis, negating to some extent
the need to manually collect details of resource use from patient
records. However, there has been debate over the completeness of
HES data and constraints in the range of activity covered (Spencer
and Davies, 2012). In addition, manual hand searching, patient
questionnaires and HES all require unit costs to be assigned to the
resource use, described as a ‘top–down’ costing approach. Use of
PLICS data for this type of economic evaluation is based on local
‘bottom–up’ costing techniques, where the costs of specific
procedures or care episodes reflect the real local expenditure
required to provide them. Analysis using a PLICS database is less
onerous, time-consuming and costly than hand searching patient
records and is unlikely to suffer potential difficulties associated
with recall bias. Local unit costs are included in each PLICS
database and the granularity and range of the data is likely to have
fewer constraints than HES data.
Table 2. Univariate regression analysis of 15-month costs
(log-scale)
Coefficient Exp(coeff) s.e. P-value
Breast cancer
Age 0.015 0.985 0.004 o0.001
IMD X3 0.064 1.066 0.093 0.491
HER2 positive 0.1454 1.157 0.083 0.082
HR positive 0.2032 0.816 0.089 0.024
Lymph node positive 0.5516 1.736 0.089 o0.001
Grade 3 0.520 1.682 0.100 o0.001
EQ-5D (at T1) 1.020 0.361 0.363 0.006
Colorectal cancer
Age 0.0135 0.987 0.027 0.006
Gender (female) 0.1178 1.125 0.399 0.139
IMD X3 0.1202 1.128 0.190 0.53
Dukes stage C 0.5291 1.697 0.173 0.003
EQ-5D (at T1) 0.202 0.817 0.246 0.413
Prostate cancer
Age 0.0097 0.990 0.420 0.012
IMD X3 0.1033 0.902 0.179 0.566
Gleason score X7 0.4834 1.622 0.179 0.008
EQ-5D (at T1) 0.433 0.649 0.448 0.336
Abbreviations: Exp(coeff)¼Expected value of the coefficient; HER2¼ human epidermal
growth factor receptor 2; HR¼ hormone receptor; IMD¼ Index of Multiple Deprivation.
Table 3. Multivariate regression analyses for 15 month costs
(log-scale)
Coefficient Exp(coeff) s.e. P-value
Breast cancer
(intercept) 9.207 9967 0.259
Age 0.008 0.992 0.003 0.016
IMD X3 0.034 1.035 0.078 0.663
HER2 positive 0.358 1.430 0.093 o0.001
HR positive 0.099 0.906 0.090 0.271
Lymph node positive 0.556 1.744 0.083 o0.001
Grade X3 0.454 1.575 0.091 o0.001
EQ-5D (at T1) 0.147 0.863 0.212 0.488
Colorectal cancer
(intercept) 9.298 10916.17 0.647
Age 0.005 0.996 0.009 0.551
Gender (female) 0.010 1.010 0.181 0.957
IMD X3 0.113 1.120 0.175 0.520
Dukes stage C 0.528 1.696 0.188 0.006
EQ-5D (at T1) 1.620 0.162 0.595 0.009
Prostate cancer
(intercept) 8.593 5393.77 0.794
Age 0.013 0.987 0.012 0.287
IMD X3 0.133 0.875 0.191 0.486
Gleason score X7 0.497 1.644 0.183 0.008
EQ-5D (at T1) 0.256 0.774 0.472 0.590
Abbreviations: Exp(coeff)¼Expected value of the coefficient; HER2¼human epidermal
growth factor receptor 2; HR¼ hormone receptor; IMD¼ Index of Multiple Deprivation.
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Figure 4. EQ-5D utility values by age, gender and tumour site at T1, T2 and T3.
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In the United Kingdom, the PLICS initiative led to coordinated
local piloting in 2009 with the primary objective of providing NHS
organisations a better understanding of their drivers of costs
(Department of Health, 2011). The intention of this system is to
provide an electronic means by which to measure the resources
consumed by individual patients. Such data may then be used to
understand variations in services. When linked with clinical care
and outcomes data, improved clinical ownership of resource
decisions and evidence-based analysis also becomes possible
(Francisci et al, 2013). PLICS is not compulsory across the NHS,
and by 2010 few Trusts had implemented the system. Early
indications suggest that it is a useful tool to provide accurate data
on spending against income (Blunt and Bardsley, 2012). This is the
first study to assign costs to the clinical cancer care pathway using
linkage between PLICS and clinical data sets. It also has the added
advantage of linked QoL data, providing proof-of-concept for a
comprehensive routine electronic data set for technology
evaluation.
This study adds substantially to the current limited literature on
the costs of hospital-based cancer care using robust, efficient and
reproducible methods. To our knowledge this is the first UK study
to report costs in this manner for the initial year after diagnosis
and certainly the largest study of its kind to date. Two previous
studies have looked at the costs of recurrent breast cancer with
estimates between d12 000 and d25 000 for the first year after
diagnosis of a recurrence in patients with a previously treated
breast cancer (Karnon et al, 2007; Thomas et al, 2009). Both
studies use a top–down HRG-based costing method. This
compares with our study’s headline 15-month cost for new breast
cancer patients of d12 595.
The cost analysis was based on the data from one of the biggest
NHS trusts in the country, which offers a range of both general and
specialist hospital services. The results are therefore likely to be
broadly generalisable across the UK population to similar sized
populations. Care should be taken when attempting to apply these
cost results in a non-UK context, as the specific configuration of
individual national health-care service provision – which has a
major impact on how and where costs are likely to be incurred –
can vary significantly from country to country. An advantage of
this study is that it enables adjustment of both costs and EQ-5D
scores based on clinical and demographic factors, allowing
greater representations of local populations with well-defined
characteristics.
Overall, this analysis found that baseline staging and related
clinical characteristics were the strongest predictors of hospital
costs. Within breast cancer significant predictors were lymph node
status, grade and molecular markers (HER2 and hormone status);
for colorectal cancer, Dukes classification and for prostate cancer
the Gleason score. Sociodemographic variables were of less
importance as predictors of cost. There was no clear association
between treatment costs and IMD. This is surprising given that
health inequalities have previously been seen to be associated with
poorer health and health outcomes and higher treatment costs
(Marmot et al, 2010). It may, however, be explained by a limitation
of the study, whereby all people involved in ePOCS had to be able
to access the internet. Inevitably, this meant that the trend
common in routine clinical trials, whereby fewer older people
living in areas of greater deprivation enroll in studies, was
exacerbated in this study (Sateren, 2002; Murthy et al, 2004).
There was a significant difference in IMD quintile between those
who consented and refused study participation (Po001), and IMD
quintile was the only significant predictor of retention in a
regression analyses. In addition, our analysis showed no correlation
between IMD and staging in contrast to evidence to suggest IMD
predicts clinical outcome (Downing et al, 2007).
Our univariate analyses showed significant differences in costs
by age, but these differences were no longer significant (at the 99%
level) in the multivariate analyses. Despite the lack of statistical
significance, a clear trend exists suggesting that older patients
(65 and over) are associated with lower costs than younger
patients. In the case of breast cancer, this may be explained by
younger patients presenting with higher disease stage, as well as
more aggressive treatment of younger patients. In colorectal and
prostate cancer it is unclear why this might be and whether this is
related to demand-side (patients actively consuming more health
care resources—e.g., contacting the doctor more frequently) or
supply-side factors (health-care professionals providing more
health care resources—e.g., conducting more tests or suggesting
more frequent visits). The absence of information about comor-
bidity is a clear limitation of this study as it is likely that
comorbidity contributes to differences in costs between age groups.
The multivariate regression of the EQ-5D scores found no
significant predictors of QoL at any time-point for the three cancer
types. The lack of significance may be a function of the relatively
limited sample size, particularly for the EQ-5D analysis due to the
limitation of missing data. The descriptive analysis on the EQ-5D
by subgroup did provide some interesting results. In line with
expectations, the QoL for patients with the three cancer types
increased over time from diagnosis and radical treatment. Breast
cancer patients appear to have the worst QoL and the smallest
improvements in QoL over time. This may be related to the
continuing psychological impact of mastectomy, especially in a
sample that is young relative to the other cancer-type patients.
There was the interesting finding that younger women with breast
cancer have worse QoL than older women. This confirms the
findings in this regard of a number of other studies (Calman, 1984;
Hopwood et al, 2007). In contrast, conventional wisdom in non-
breast cancer patients based on many analyses of EQ-5D data,
including population norms and Health Survey for England data,
has concluded that QoL declines with age (Maheswaran et al,
2013). Indeed, we see in the prostate and colorectal cancer groups
that older patients have lower EQ-5D scores, even when stratified
by gender. It is not clear why this QoL reversal by age group exists
in breast cancer. It is possible that the impact of cancer is greater in
younger patients due to greater psychological distress, or appears
greater due to questionnaire responses being reference based (to
the health of similarly aged-peers) or expectation-based. A number
of mean between-group differences in QoL appeared non-trivial
and in the order of magnitude of a difference that could be
considered important (between 0.06 and 0.12) (Pickard et al,
2007a). These include the differences between breast and prostate
cancer patients, differences between age groups in breast cancer
and between the highest and lowest IMD groups. The QoL of the
three sets of cancer patients appears roughly in line with
population norms with the exception that younger breast cancer
Table 4. Comparison of EQ-5D utility scores with population
norms
Study sample
Reference
population P-value
Breast
T1 0.755 0.823 0.000
T2 0.776 0.826 0.002
T3 0.785 0.826 0.018
Colorectal
T1 0.765 0.793 0.130
T2 0.802 0.793 0.598
T3 0.812 0.794 0.362
Prostate
T1 0.838 0.780 0.002
T2 0.868 0.780 0.000
T3 0.868 0.779 0.000
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patients experience a decrement and the patients with prostate
cancer have consistently higher scores. The colorectal cancer
patients are almost the same as the population norms. The
recruitment and retention within the ePOCS study is biased owing
to both deprivation and age, in common in many trials and
exaggerated in ePOCS owing to the reliance on information
technology. This may explain higher than expected QoL. The
association seen between T1 EQ-5D scores and cumulative costs is
intuitive given that more intensive treatments such as chemother-
apy and radiotherapy may cost more and increase morbidity.
LTHT’s PLICS system is constructed using nationally recog-
nised costing principles and methods, supplemented where
appropriate by locally determined rules and arrangements relevant
and appropriate to PLICS, and having been determined in
consultation with divisional clinical, operational and finance
representatives initially and since by regular review. Effort to date
has predominantly been focussed on refining the inputs to the
system and, at the time of writing, there has been no systematic,
widespread review of PLICS outputs across LTHT among
operational and clinical staff. This is something which, following
a recent Trust restructuring and the creation of Clinical Service
Units, the Trust is now embarking upon using 2012–2013 PLICS
data. Until this systematic validation takes place, LTHT PLICS data
must be treated with caution. In addition, the Trust is conscious of
a number of areas of NHS service provision in which the linking of
costs to patients is still not possible, such as catering services and
housekeeping; this may impact differentially on services evaluated.
This analysis considered hospital post-diagnosis costs over
a 15-month follow-up period. A full analysis of costs requires
additional consideration of both primary and community care
costs, as well as costs incurred pre-diagnosis and in the longer
term. We will be attempting to quantify these additional costs in
future planned analyses.
This paper has described an analysis based on data generated by
using a novel method of capturing patient-reported outcome data
and linking that with clinical and cost data from hospitals. The
feasibility and utility of such data linkage now being evident,
further efforts to routinely collect and link such data is encouraged.
The results described here will be of use to health economic
modellers requiring cost and utility estimates to populate decision-
analytical models. The results have implications for health
economic analysis and modelling in cancer. First, costs decline
rapidly after the initial treatment phase but have small peaks
around the routine visit time points; thus analysts should have
differential cost estimates in year 1 vs subsequent years.
Unsurprisingly, costs differ not only by disease stage but also
more unexpectedly by age with younger patients being associated
with greater costs. The latter point is worthy of further
investigation. The QoL of patients recovering from cancer does
not appear substantively different from age-specific population
norms with the exception of younger women with breast cancer,
although this finding may be a result of potential patient selection
bias as previously discussed. Future economic analyses of breast
cancer interventions should bear in mind the QoL decrement that
accompanies breast cancer in younger groups in addition to the
time-varying and subgroup-varying nature of secondary health-
care costs.
ACKNOWLEDGEMENTS
We would like to thank the Corporate Finance Department of
LTHT including Wendy Allott and Joe Selfridge who provided data
from the LTHT PLICS. We note that they take no responsibility for
the analysis or interpretation of the data. This work was funded by
Macmillan Cancer Support.
REFERENCES
Ashley L, Jones H, Forman D, Newsham A, Brown J, Downing A, Velikova G,
Wright P (2011a) Feasibility test of a UK-scalable electronic system for
regular collection of patient-reported outcome measures and linkage with
clinical cancer registry data: the electronic Patient-reported Outcomes
from Cancer Survivors (ePOCS) system. BMC Med Inf Decis Making
11: 66.
Ashley L, Jones H, Thomas J, Forman D, Newsham A, Morris E,
Johnson O, Velikova G, Wright P (2011b) Integrating cancer survivors’
experiences into UK cancer registries: design and development of the
ePOCS system (electronic Patient-reported Outcomes from Cancer
Survivors). Br J Cancer 105: S74–S81.
Ashley L, Jones H, Thomas J, Newsham A, Downing A, Morris E, Brown J,
Velikova G, Forman D, Wright P (2013) Integrating patient reported
outcomes with clinical cancer registry data: a feasibility study of the
electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS)
system. J Med Internet Res 15: e230.
Black N (2013) Patient reported outcome measures could help transform
healthcare. BMJ 346: f167.
Blunt I, Bardsley M (2012) Patient-Level Costing: Can it Yield Efficiency
Savings? London.
Brown ML, Riley GF, Potosky AL, Etzioni RD (1999) Obtaining long-term
disease specific costs of care: application to Medicare enrollees diagnosed
with colorectal cancer. Med Care 37: 1249–1259.
Calman KC (1984) Quality of life in cancer patients–an hypothesis. J Med
Ethics 10: 124–127.
Department for Communities and Local Government (2011) English Indices of
Deprivation 2010: Guidance Document. Crown Copyright: London.
Department of Health (2011) Patient Level Information & Costing Systems
(PLICS) & Reference Costs Best Practice Guide London.
Department of Health Payment by Results team (2012) A Simple Guide to
Payment by Results London.
De Oliveira C, Bremner KE, Pataky R, Gunraj N, Chan K, Peacock S,
Krahn MD (2013) Understanding the costs of cancer care before and after
diagnosis for the 21 most common cancers in Ontario: a population-based
descriptive study. CMAJ Open 1: E1–E8.
Downing A, Prakash K, Gilthorpe MS, Mikeljevic JS, Forman D (2007)
Socioeconomic background in relation to stage at diagnosis, treatment and
survival in women with breast cancer. Br J Cancer 96: 836–840.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien B, Stoddar GL (2005)
Methods For the Economic Evaluation of Health Care Programmes.
3rd edn, Oxford University Press: Oxford, UK.
Francisci S, Guzzinati S, Mezzetti M, Crocetti E, Giusti F, Miccinesi G, Paci E,
Angiolini C, Gigli A (2013) Cost profiles of colorectal cancer patients in
Italy based on individual patterns of care. BMC Cancer 13: 329.
Gaughan J, Mason A, Street A, Ward P (2012) English hospitals can improve
their use of resources: an analysis of costs and length of stay for ten
treatments.
Glaser AW, Fraser LK, Corner J, Feltbower R, Morris EJA, Hartwell G,
Richards M (2013) Patient-reported outcomes of cancer survivors in
England 1-5 years after diagnosis: a cross-sectional survey. BMJ Open 3:
e002317.
Gudex C, Kind P, Williams A (1995) A Social Tariff for EuroQol: Results From
a UK General Population Survey. Univerisity of York, Centre for Health
Economics: UK.
Hopwood P, Haviland J, Mills J, Sumo G, M Bliss J (2007) The impact of age
and clinical factors on quality of life in early breast cancer: an analysis of
2208 women recruited to the UK START Trial (Standardisation of Breast
Radiotherapy Trial). Breast 16: 241–251.
Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA (2007) Health care costs
for the treatment of breast cancer recurrent events: estimates from
a UK-based patient-level analysis. Br J Cancer 97: 479–485.
Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health
status: results from a United Kingdom national questionnaire survey.
BMJ 316: 736–741.
Krahn MD, Zagorski B, Laporte A, Alibhai SMH, Bremner KE, Tomlinson G,
Warde P, Naglie G (2010) Healthcare costs associated with prostate
cancer: Estimates from a population-based study. BJU Int 105: 338–346.
Maheswaran H, Petrou S, Rees K, Stranges S (2013) Estimating EQ-5D utility
values for major health behavioural risk factors in England. J Epidemiol
Community Health 67: 172–180.
Costs of cancer care BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.644 955
Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of
the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst
103: 117–128.
Marmot M, Atkinson T, Bell J (2010) Fair society, healthy lives. Available at
http://www.instituteofhealthequity.org/projects/fair-society-healthy-lives-
the-marmot-review.
Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical
trials: race-, sex-, and age-based disparities. JAMA 291: 2720–2726.
Newsham AC, Johnston C, Hall G, Leahy MG, Smith AB, Vikram A,
Donnelly AM, Velikova G, Selby PJ, Fisher SE (2011) Development of an
advanced database for clinical trials integrated with an electronic patient
record system. Comput Biol Med 41: 575–586.
Pickard AS, Neary MP, Cella D (2007a) Estimation of minimally important
differences in EQ-5D utility and VAS scores in cancer. Heal Qual Life
Outcomes 5: 70.
Pickard AS, Wilke CT, Lin HW, Lloyd A (2007b) Health utilities using the
EQ-5D in studies of cancer. Pharmacoeconomics 25: 365–384.
R Development Core Team (2009) R: A language and environment for
statistical computing. R Foundation for Statistical Computing: Vienna,
Austria, ISBN 3-900051-07-0. http://www.R-project.org.
Sateren WB (2002) How sociodemographics, presence of oncology specialists,
and hospital cancer programs affect accrual to cancer treatment trials.
J Clin Oncol 20: 2109–2117.
Spencer SA, Davies MP (2012) Hospital episode statistics: improving the
quality and value of hospital data: a national internet e-survey of hospital
consultants. BMJ Open 2: e001651.
The EuroQol Group (1990) EuroQol-a new facility for the measurement
of health-related quality of life. Health Policy (New York) 16: 199–208.
Thomas RJ, Williams M, Marshall C, Glen J, Callam M (2009) The total
hospital and community UK costs of managing patients with relapsed
breast cancer. Br J Cancer 100: 598–600.
Tilson L, Sharp L, Usher C, Walsh C, S W, O’Ceilleachair A, Stuart C,
Mehigan B, John Kennedy M, Tappenden P, Chilcott J, Staines A,
Comber H, Barry M (2012) Cost of care for colorectal cancer in
Ireland: a health care payer perspective. Eur J Health Econ 13:
511–524.
Vogl M (2012) Improving patient-level costing in the English and the German
‘‘DRG’’system. Health Policy (New York) 109(3): 290–300.
Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A,
Brown ML (2008) Cost of care for elderly cancer patients in the United
States. J Natl Cancer Inst 100: 630–641.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 4.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
BRITISH JOURNAL OF CANCER Costs of cancer care
956 www.bjcancer.com |DOI:10.1038/bjc.2014.644
